Full-Time
Senior Automation Engineer
Posted on 5/9/2026
Sartorius
5,001-10,000 employees
Laboratory instruments and bioprocess solutions
No salary listed
Schwalmstadt, Germany
Remote
Remote options available; flexible work schedules.
 Electrical Engineering (1) |
|---|
- Master’s degree in Science; a Ph.D. is considered a plus
- At least five years of industry experience in process automation or related fields
- Deep understanding of process automation and related standards such as ISA‑95 and ISA‑88
- Demonstrated technical leadership within product development projects, including stakeholder management
- Strong proficiency in Siemens PLCs and programming in Structured Control Language (SCL) using TIA Portal
- Familiarity with computer systems validation practices (GAMP)
- An understanding of TOGAF principles complements your skillset
- Experience in upstream and downstream bioprocessing is advantageous, though not required
- Lead in designing and implementing process automation assets for our modular automation platform based on Siemens PLC and WinCC OA technology
- Translating process requirements into robust automation architectures, control concepts, and software designs as part of your daily work
- Review and verify functional and design specifications to ensure quality and compliance
- Acting as a hands-on technical authority, you contribute directly to PLC programming, including code creation, review, and approval
- Mentor and guide automation engineers and developers, fostering technical excellence within the team
- Work closely with project managers, you help ensure end-to-end solution viability and successful delivery
- Support for project planning includes effort estimation and technical risk management
Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Göttingen, Germany
Founded
1870
Simplify's Take
What believers are saying
- Order intake hit highest Q4 2025 level, book-to-bill above one.
- Equity ratio reached 48.7% after €1B capital increase in 2024.
- 6-10% sales growth projected for 2026 with margins above 30%.
What critics are saying
- Trump tariffs hit German imports; US manufacturing lags by 2027.
- Danaher's Cytiva bundling steals share from Sartorius platforms.
- Biotech funding drop 36% in 2024 cuts customer equipment capex.
What makes Sartorius unique
- Sartorius leads in single-use ultrafilters like Sartocon Slice 50.
- Ann Arbor $100M Center of Excellence boosts bioanalytics innovation.
- SIMCA-online software excels in batch process monitoring.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Sartorius who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget
Company News
Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.
Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.
Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.
Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.
Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.